To understand the prognostic significance of CDK4 or CDK6 expression in wild type p53 or mutant p53, we immunohistochemically evaluated a clinical cohort of 1055 CDK4/6i-naïve breast cancers. This evidence concerns the gene TP53 and breast carcinoma.